Gatehouse Bio Extends Its Partnership with AstraZeneca to Develop RNA Therapeutics for Heart Failure
BOSTON–(BUSINESS WIRE)–Gatehouse Bio, a pioneer in small RNA therapeutics, and AstraZeneca, a global, science-led biopharmaceutical company, are advancing their partnership, to create RNA therapeutics for the treatment of heart failure with preserved ejection fraction (HFpEF).
Gatehouse Bio collaborates with AstraZeneca to accelerate new drug discovery
Collaboration will use Gatehouse Bio’s AI-Powered Analytics Platform to identify potential drug targets in respiratory and cardiovascular diseases
Gatehouse Bio Receives FDA Support for AI-Powered Pathway Analytics Platform
Platform uncovers biomarkers that track progression of Huntington’s disease 20 years before symptomatic onset
Gatehouse Bio to Accelerate its Biomarker Discovery Platform and Services at IndieBio
… early-stage biotech startup based in Boston who has developed a software platform technology to identify small RNA biomarkers, announced today it will participate in the IndieBio Accelerator Program in San Francisco, CA.
